ES3027238T3 - Pd1 and vegfr2 dual-binding agents - Google Patents
Pd1 and vegfr2 dual-binding agents Download PDFInfo
- Publication number
- ES3027238T3 ES3027238T3 ES20789105T ES20789105T ES3027238T3 ES 3027238 T3 ES3027238 T3 ES 3027238T3 ES 20789105 T ES20789105 T ES 20789105T ES 20789105 T ES20789105 T ES 20789105T ES 3027238 T3 ES3027238 T3 ES 3027238T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- leu
- amino acid
- lys
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914747A GB201914747D0 (en) | 2019-10-11 | 2019-10-11 | PD1 and vegfr2 dual-binding agents |
| GBGB2013180.1A GB202013180D0 (en) | 2019-10-11 | 2020-08-24 | Pd1 and vegfr2 dual-binding agents |
| PCT/EP2020/078427 WO2021069670A1 (en) | 2019-10-11 | 2020-10-09 | Pd1 and vegfr2 dual-binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3027238T3 true ES3027238T3 (en) | 2025-06-13 |
Family
ID=68619556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20789105T Active ES3027238T3 (en) | 2019-10-11 | 2020-10-09 | Pd1 and vegfr2 dual-binding agents |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240101674A1 (OSRAM) |
| EP (3) | EP4570824A3 (OSRAM) |
| JP (2) | JP7689116B2 (OSRAM) |
| KR (1) | KR20220091490A (OSRAM) |
| CN (2) | CN114981301B (OSRAM) |
| AU (1) | AU2020365021A1 (OSRAM) |
| CA (2) | CA3156096C (OSRAM) |
| DK (1) | DK4041763T3 (OSRAM) |
| ES (1) | ES3027238T3 (OSRAM) |
| FI (1) | FI4041763T3 (OSRAM) |
| GB (2) | GB201914747D0 (OSRAM) |
| HR (1) | HRP20250523T1 (OSRAM) |
| HU (1) | HUE071341T2 (OSRAM) |
| IL (1) | IL292158A (OSRAM) |
| LT (1) | LT4041763T (OSRAM) |
| PL (1) | PL4041763T3 (OSRAM) |
| PT (1) | PT4041763T (OSRAM) |
| RS (1) | RS66837B1 (OSRAM) |
| SI (1) | SI4041763T1 (OSRAM) |
| WO (1) | WO2021069670A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CN116143935A (zh) * | 2021-11-22 | 2023-05-23 | 杭州翰思生物医药有限公司 | 重组抗体及其应用 |
| CN119654343A (zh) * | 2022-08-09 | 2025-03-18 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| CN118620082A (zh) * | 2023-03-10 | 2024-09-10 | 南京维立志博生物科技有限公司 | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| JP6312659B2 (ja) * | 2012-05-31 | 2018-04-18 | ジェネンテック， インコーポレイテッド | Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) * | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| DK3356411T3 (da) | 2015-10-02 | 2021-09-06 | Hoffmann La Roche | Bispecifikke antistoffer, der er specifikke for PD1 og TIM3 |
| CN109893654B (zh) * | 2017-12-11 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂治疗肿瘤的方法 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| JP2022512822A (ja) | 2018-11-06 | 2022-02-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗ｐｄ－１抗体の使用 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
-
2019
- 2019-10-11 GB GB201914747A patent/GB201914747D0/en not_active Ceased
-
2020
- 2020-08-24 GB GBGB2013180.1A patent/GB202013180D0/en not_active Ceased
- 2020-10-09 PL PL20789105.2T patent/PL4041763T3/pl unknown
- 2020-10-09 WO PCT/EP2020/078427 patent/WO2021069670A1/en not_active Ceased
- 2020-10-09 RS RS20250448A patent/RS66837B1/sr unknown
- 2020-10-09 US US17/768,013 patent/US20240101674A1/en active Pending
- 2020-10-09 EP EP25159487.5A patent/EP4570824A3/en active Pending
- 2020-10-09 CA CA3156096A patent/CA3156096C/en active Active
- 2020-10-09 LT LTEPPCT/EP2020/078427T patent/LT4041763T/lt unknown
- 2020-10-09 PT PT207891052T patent/PT4041763T/pt unknown
- 2020-10-09 EP EP20789105.2A patent/EP4041763B1/en active Active
- 2020-10-09 CA CA3289307A patent/CA3289307A1/en active Pending
- 2020-10-09 SI SI202030611T patent/SI4041763T1/sl unknown
- 2020-10-09 JP JP2022521074A patent/JP7689116B2/ja active Active
- 2020-10-09 CN CN202080075802.2A patent/CN114981301B/zh active Active
- 2020-10-09 ES ES20789105T patent/ES3027238T3/es active Active
- 2020-10-09 CN CN202511932691.3A patent/CN121758618A/zh active Pending
- 2020-10-09 HR HRP20250523TT patent/HRP20250523T1/hr unknown
- 2020-10-09 HU HUE20789105A patent/HUE071341T2/hu unknown
- 2020-10-09 EP EP25212556.2A patent/EP4671279A2/en active Pending
- 2020-10-09 KR KR1020227014433A patent/KR20220091490A/ko active Pending
- 2020-10-09 DK DK20789105.2T patent/DK4041763T3/da active
- 2020-10-09 FI FIEP20789105.2T patent/FI4041763T3/fi active
- 2020-10-09 AU AU2020365021A patent/AU2020365021A1/en active Pending
-
2022
- 2022-04-11 IL IL292158A patent/IL292158A/en unknown
-
2025
- 2025-02-18 US US19/056,312 patent/US12479920B2/en active Active
- 2025-05-26 JP JP2025087525A patent/JP2025134713A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240101674A1 (en) | 2024-03-28 |
| JP2025134713A (ja) | 2025-09-17 |
| FI4041763T3 (fi) | 2025-05-15 |
| GB201914747D0 (en) | 2019-11-27 |
| IL292158A (en) | 2022-06-01 |
| CA3156096A1 (en) | 2021-04-15 |
| EP4570824A2 (en) | 2025-06-18 |
| CA3289307A1 (en) | 2026-03-02 |
| PT4041763T (pt) | 2025-05-16 |
| CN114981301B (zh) | 2026-04-14 |
| SI4041763T1 (sl) | 2025-08-29 |
| EP4041763A1 (en) | 2022-08-17 |
| GB202013180D0 (en) | 2020-10-07 |
| CN114981301A (zh) | 2022-08-30 |
| PL4041763T3 (pl) | 2025-07-07 |
| EP4041763B1 (en) | 2025-02-26 |
| US12479920B2 (en) | 2025-11-25 |
| RS66837B1 (sr) | 2025-06-30 |
| WO2021069670A1 (en) | 2021-04-15 |
| LT4041763T (lt) | 2025-06-10 |
| AU2020365021A1 (en) | 2022-05-26 |
| DK4041763T3 (da) | 2025-05-19 |
| JP7689116B2 (ja) | 2025-06-05 |
| US20250243276A1 (en) | 2025-07-31 |
| EP4570824A3 (en) | 2025-06-25 |
| CN121758618A (zh) | 2026-03-31 |
| HRP20250523T1 (hr) | 2025-07-04 |
| KR20220091490A (ko) | 2022-06-30 |
| EP4671279A2 (en) | 2025-12-31 |
| JP2022553908A (ja) | 2022-12-27 |
| CA3156096C (en) | 2026-03-17 |
| HUE071341T2 (hu) | 2025-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275657B1 (en) | c-kit antibodies | |
| US10858435B2 (en) | PD1 binding agents | |
| US12479920B2 (en) | PD1 and VEGFR2 dual-binding agents | |
| US12415861B2 (en) | Anti C-MET antibodies | |
| US11851460B2 (en) | PD1 binding agents | |
| CA3117371A1 (en) | Methods of administering anti-tim-3 antibodies | |
| US11655300B2 (en) | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof | |
| HK40075900B (en) | Pd1 and vegfr2 dual-binding agents | |
| HK40075900A (en) | Pd1 and vegfr2 dual-binding agents |